Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07451158

Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal TENS Device for Migraine Treatment

Multicenter, double-blind, and randomized controlled trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine treatment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Electrical stimulator

Hangzhou, Zhejiang, 311100, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged between 18 and 75;
  • According to the diagnostic criteria of the International Classification of Headache Disorders (ICHD-III), the diagnosis is episodic migraine with or without aura or probable migraine with or without aura;
  • The duration of the illness is at least 12 months;
  • The age of onset of the first migraine is less than 50 years old;
  • During the screening period of 4 weeks, there were 2-8 episodes of headache, with moderate or severe pain intensity;
  • Before screening, the subjects should provide their previous medical records as much as possible;
  • Participants can distinguish migraines from other conditions, including tension-type headaches and cluster headaches
  • Understand and adhere to the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing;

Exclusion criteria

  • Pregnant and lactating women;
  • Suffering from arrhythmia or other heart diseases (such as ischemic heart disease, coronary artery spasm, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, angina pectoris);
  • Have undergone surgery within the past 6 months;
  • Recent stroke or transient ischemic attack;
  • Equipped with a pacemaker;
  • History of previous seizures;
  • Metal implants in the head;
  • Patients with clinical evidence of brain damage;
  • Chronic pain associated with other diseases;
  • Use antipsychotic drugs;
  • Those who are intolerant to neuroregulators;
  • Employees of the research center or their immediate family members.
  • There is a condition or anomaly that the investigator believes may affect patient safety or data quality

Treatment and study plan

Trail of Ultral-distal Transcutaneous Electrical Nerve Stimulation

Device

When subjects report experiencing or impending headache episodes, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) therapy in the treatment area. Prior to activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Subsequently, activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. A safety follow-up (telephone consultation or online questionnaire) should be completed one week after the treatment session.

Fake Stimulus

Device

When subjects experience or anticipate headache onset, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) in a non-treatment area. Before activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Then activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. Complete a safety follow-up one week after the same-day treatment (via telephone consultation or online questionnaire).

Primary outcomes

  1. Reduce the intensity of migraine

    Time frame: Baseline and 2 hours post-treatment

    After treatment, participants rated their headache intensity as 0 (no pain =0 points, mild =1 point, moderate =2 points, severe =3 points).

  2. the pre-selected accompanying symptoms

    Time frame: Baseline and 2 hours post-treatment

    Participants no longer experienced the pre-selected accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) after 2 hours of treatment.

Secondary outcomes

  1. pain relief

    Time frame: Baseline and 2 hours post-treatment

    Pain relief measured by Visual Analogue Scale (VAS):Number of participants transitioning from moderate to mild pain at 2 hours post-treatment.

  2. returned to normal function

    Time frame: Baseline and 2 hours post-treatment

    Number of participants who resumed normal daily activities (e.g., ability to ambulate freely or return to work/school) by 2 hours post-treatment.

  3. Use of acute treatment drugs

    Time frame: Baseline and 24 hours post-treatment

    Use of acute treatment drugs within 24 hours of treatment

  4. recurrence of migraine

    Time frame: Baseline and 2-24 hours post-treatment

    No recurrence of migraine attack occurred within 2-24 hours after treatment

  5. recurrence of migraine2

    Time frame: Baseline and 2-48 hours post-treatment

    No recurrence of migraine attack occurred within 2-48 hours after treatment

  6. pain-free status

    Time frame: Baseline and 15,30,45,60, and 90 minutes post-treatment

    Participants achieved pain-free status (VAS score 0) at 15,30,45,60, and 90 minutes post-treatment, having progressed from moderate to severe pain.

  7. symptoms free

    Time frame: Baseline and 15,30,45,60, and 90 minutes post-treatment

    Participants' accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) did not reappear at 15,30,45,60, and 90 minutes after treatment

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Collaborators

  • Hangzhou Hospital of Traditional Chinese Medicine
  • Huzhou Central Hospital
  • Ningbo Medical Center Lihuili Hospital
  • The first people Hospital of Linhai

Registry information

Official study title

Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine Treatment

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 5, 2026
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.